Background. To analyze the time trends of the viral subtype distributions according to gender, risk group, and geographical origin of the patients in 1128 primary human immunodeficiency virus type 1 infection (PHI), diagnosed in France (1996France ( -2010. To study whether the viral diversity had an impact on the virological and immunological responses in patients initiating combined antiretroviral therapy (cART) soon after infection.
forms (CRFs) and more than 50 different CRFs have been described (http://www.hiv.lanl.gov). In 2004-2007, subtype C accounted for nearly half (48%) of all infections worldwide, followed by subtype A (12%), subtype B (11%), CRF02_AG (8%), CRF01_AE (5%), subtype G (5%), and subtype D (2%) [1] . Subtype B predominates in North America, the Caribbean, Latin America, Western and Central Europe, and Australia, but the prevalence of non-B subtypes in Europe has increased during the last 2 decades [2] [3] [4] [5] [6] [7] . Although subtype B strains were still the most prevalent in France, non-B viruses were isolated from 26% of the primary HIV-1 infections (PHIs) in 2005-2006 compared to 10% in 1996-1998 [8] . In chronic newly diagnosed HIV-1 individuals, non-B subtypes represented 10% of the cases in 1998, and 40%-50% in 2005-2007 [9, 10] . The diversity of HIV-1 poses a significant challenge to the reliability of screening, diagnostic, and patient-monitoring assays [11] . Subtypes may differ in transmissibility [12, 13] and in disease progression [14] [15] [16] . The differences among HIV-1 genetic forms may also impact the response to antiretroviral therapy and the development of drug resistance [17] [18] [19] [20] [21] . The responses of non-B subtypes to combined antiretroviral therapy (cART) have been measured in several adult or pediatric cohort studies [22] [23] [24] [25] [26] . Notably, all of these studies were conducted in chronically infected patients.
In the study presented herein, we characterized the genetic diversity and molecular epidemiology of HIV-1 by determining the frequencies of distinct subtypes and of CRFs responsible for PHIs in patients diagnosed in France between 1996 and 2010. We also analyzed the effects of the HIV-1 subtype (B, CRF02_AG or other non-B subtypes) on the virological and immunological responses when cART was initiated during PHI.
METHODS

Study Population
The study population comprised patients enrolled during PHI in the multicenter ANRS PRIMO cohort. The Paris Cochin Ethics Committee approved the protocol, and all the subjects gave their written informed consent. Recent infection was confirmed by a negative or indeterminate enzyme-linked immunosorbent assay (ELISA) for anti-HIV antibodies associated with the presence of p24 antigenemia or of HIV-1-RNA in the plasma; or a Western blot (WB) profile compatible with ongoing seroconversion; or an initially negative test for HIV antibodies followed within 6 months by a positive HIV serology. At enrollment, a physical examination was performed, and blood samples ( plasma and peripheral blood mononuclear cells) were collected for immunological and virological studies [27] . All patients were antiretroviral-naive at the time of inclusion in the cohort.
Data collected at baseline, at 1 month (M1), M3, M6, and every 6 months thereafter included all CD4+ T-cell counts and viral loads (VLs) measured until the last follow-up.
Genotypic resistance tests were performed at baseline on HIV-RNA from plasma using the consensus technique of the AC11 ANRS Resistance group (http://www.hivfrenchresistance.org) [28] .
Subtype Determination
Phylogenetic analysis of RT gene sequences was used to determine HIV subtype. In a few cases (n = 6), sequences were unavailable, and serology methods were used [29] . The phylogenetic relationships of the RT sequences were estimated from sequence comparisons with previously reported representatives of group M including reference sequences available in the LANL HIV databases (up to CRF 48; http://www.hiv.lanl. gov). The sequences were aligned using Clustal X [30] . Phylogenetic trees were constructed by the neighbor-joining method, and reliability of the branching orders was implemented using a bootstrap approach (1000) [31] . Bootstrap values ≥70% were considered definitive for assigning a sequence to a subtype or CRF.
Analysis for Intersubtype Mosaicism
We used several additional analyses for the viruses not classified by the phylogenetic analysis. The recombinant structure of the reverse transciptase genes was analyzed using Simplot 3.5.1 software as described elsewhere [32, 33] .
Statistical Analysis
Percentages were compared by using χ 2 or Fisher exact tests.
For continuous variables, Wilcoxon or Kruskal-Wallis tests were used. Response to cART was studied among patients who initiated cART at the time of primary infection (ie, <1 month following diagnosis) and were followed for at least 12 months. Patient follow-up was censored at the first treatment interruption (lasting >1 month). The percentage of patients with viral suppression (VL <400 copies/mL) was assessed at M6 (±1.5 months), M12 (±1.5 months), and M24 (±1.5 months), and compared by subtype (B, CRF02, other non-B). Viral suppression defined by a VL <50 copies/mL was studied in an analysis limited to the patients who initiated cART in 1999 or later (in this period, the detection limits of HIV-RNA assays were ≤50 copies/mL for 88% of the recorded measurements). Trends in CD4 + T-cell counts after cART initiation were modeled using a linear mixed-effects model (to take into account the correlation between measurements in the same subject) with 3 slopes (including random effects for the intercept and the 3 slopes); the best model (Akaike criterium) was obtained with changes of the slopes at M1 and M18. The square root transformation of the CD4 + T-cell count was used to fulfill the model assumption. The analysis included all measurements recorded from the date of cART initiation to the first interruption or the end of follow-up (if no cART interruption). The effect of the subtypes was assessed by introducing interaction terms between the variable "subtype" (categorized as B, CRF02, or other non-B) and the intercept, and between subtype and each slope. A multivariate model with adjustment for gender and baseline VL was performed. Sensitivity analysis was also conducted by (i) restricting the analysis to the subset of virological responders, ie, patients who achieved viral suppression <400 copies/mL at M6, M12, and M24; (ii) restricting the analysis to patients whose first cART regimen consisted of 2 nucleoside reverse transcriptase inhibitor (NRTI) + 1 boosted protease inhibitor (PI/r); and (iii) excluding patients native to sub-Saharan Africa. Statistical analyses were carried out with SAS version 9.2 (SAS Institute Inc, Cary, North Carolina).
RESULTS
Study Population and Baseline Characteristics
Between 1996 and September 2010, 1128 patients were enrolled in the ANRS PRIMO Cohort: 948 (84.0%) patients were men; the median CD4 + T-cell count and median HIV-1 RNA level were 518/mm 3 (range, 22-1542) and 5.10 log 10 copies/ mL (<1.30-8.33), respectively. Subtype B was the most prevalent virus subtype (74.7%). The non-B subtype strains were identified in 285 patients and exhibited a wide diversity. Six strains were classified as non-B by serotyping [29] . CRF02_AG was evident in 156 patients (54.7%), A was in 18 patients (6.3%), C in 12 patients (4.2%), G in 11 patients (3.8%), F in 10 patients (3.5%), D in 9 patients (3.1%), CRF01_AE in 8 patients (2.8%), CRF06_cpx in 8 patients (2.8%), CRF12_BF in 3 patients (1.1%), CRF09_cpx in 2 patients (0.7%), and CRF27_cpx [33] in 2 patients (0.7%). The J subtype, CRF11_cpx, CRF14_BG, CRF18_cpx, CRF42_BF, and CRF45_cpx were each found in one patient (0.3%). The RT gene phylogenetic analysis left 34 strains (11.9%) undetermined, as they did not cluster with any known subtype or CRF. Among them, we identified 6 (2.1%) unique recombinant form (URF) BC strains [34] . The bootscan analysis of the 28 remaining URF strains exhibited a large diversity of URFs including subtype A in 14 cases (data not shown).
The frequency of patients infected with a non-B subtype increased from 15.8% (27/171) before 2000 to 27.9% (156/558) for all patients enrolled after 2004 (P trend = .003).
The distribution of the subtypes according to gender, risk group of infection, and origin of patients is shown in Table 1 . Of the 812 men born in France, 16.5% were infected with a non-B subtype. Conversely, among the 40 men born in subSaharan Africa, 9 (22.5%) harbored a subtype B virus, 8 of them being men who have sex with men (MSM). In sum, 14.9% of the 752 MSM (96 French, 6 sub-Saharan African, and 10 men born in other countries) were infected with a non-B strain. We observed a significant increase in the frequency of non-B strains among French MSM, from 7% before 2000 to 11.6% between 2000 and 2004 and 18% after 2004 (P trend = .002). For heterosexual men (n = 120), all those 22 originating from sub-Saharan Africa were infected with a non-B strain, whereas 38.7% of the 80 French men were infected with a non-B virus.
In women, 120 were born in France, 43% of them being infected with a subtype non-B virus; 34 of the 35 sub-Saharan African women were infected with a non-B strain.
The prevalence of strains resistant to at least 1 antiretroviral drug was higher in subjects infected with a B subtype than in those infected with a non-B subtype (14.2% vs 7.4%; P = .003) without different patterns of resistance between the 2 groups.
Virological and Immunological Response by Subtype
Among the 1128 patients, 488 (43.3%) initiated cART at the time of PHI diagnosis and had a follow-up of at least 1 year. Among these patients, 373 were infected with a B subtype (76.4%), 56 with a CRF02_AG strain, and 59 with another non-B subtype virus (including 10 undetermined strains) ( Table 2 ). Women and patients from sub-Saharan African origin were more often infected with a non-B subtype. The median CD4 + T-cell count was significantly lower in the patients infected with a CRF02_AG virus than in patients infected with a subtype B virus or another non-B subtype virus ( Table 2 ). The increase in non-B subtypes was slightly less pronounced among treated patients compared to the whole PRIMO population: this is due to the fact that the percentage of patients initiating cART during primary infection has decreased over time at least until 2008, whereas the percentage of non-B subtypes was increasing in the meantime. At M6, M12, and M24 months, virological suppression (VL <400 copies/mL) among patients infected with a non-B virus was similar or even higher to that of patients infected with a subtype B virus (Table 3) . Comparing subtype CRF02_AG and other non-B subtypes, the virological responses were similar at all time points.
Several sensitivity analyses were performed, which led to similar results. As geographic origin may be a critical issue for the virological response, we further did not consider patients originating from sub-Saharan Africa. Among the 457 remaining patients (87 non-B subtypes), virological responses were still similar or better in patients infected with a non-B subtype compared to patients infected with a subtype B virus. Similar results were observed only when analyzing subjects who initiated a boosted-PI containing regimen, or only patients infected with a nonresistant strain. We also studied virological responses defined by plasma HIV-RNA levels <50 copies/mL in an analysis restricted to the 390 patients who initiated cART after 1999. Virological response in patients infected with a non-B subtype was similar to patients infected with a subtype B virus. The immunological responses to cART are outlined in Figure 1 . Trends in CD4 + T-cell count after cART initiation were modeled using a piecewise linear mixed-effects model with 3 slopes (0-1 month, 1-18 months, and >18 months) ( Table 4 ). The 0-1 month slope did not differ significantly according to subtype. Patients infected with a non-B subtype had a better immunological response between 1 and 18 months (+0.1052, P = .0001) compared to patients infected with a subtype B virus. The 1-18 month immunological responses for patients infected with a CRF02_AG strain were better than those of patients infected with a B subtype (P < .0001), even after adjusting for gender and baseline plasma HIV-RNA levels (P < .0001). Further adjustment for baseline observed CD4 did not modify the results. The mean CD4 + T-cell count increase between 1 and 18 months was also higher for patients infected with other non-B viruses than for those infected with a B subtype, but this difference was of borderline significance in the multivariate analysis (P = .07). We conducted sensitivity analyses by considering only those patients who initiated 2 NRTI +1 PI/r or only virological responders and found similar results. When the analysis was restricted to patients not originating from sub-Saharan Africa, the baseline CD4 + T-cell counts according to the subtype were similar, but the 1-18 month CD4 + T-cell count increase was still better in subjects infected with a CRF02_AG strain than in those infected with a B subtype. With a simpler 2-slope model of the CD4 + T-cell increases (slopes: 0-6 months and >6 months), but with a lower fit according to the Akaike criterion, we also found a better second-phase increase in CD4 for the non-B subtypes, after a similar first slope.
DISCUSSION
Here we report data for 15 years of an ongoing national surveillance system of HIV-1 subtypes and CRFs in PHI patients included in the ANRS PRIMO cohort. This study has been conducted over the entire French territory, including the French West Indies. Our results show that, although the HIV-1 B subtype is still predominant, non-B subtypes are now present in all French regions, and they are increasing in frequency, reaching 27.9% as from 2005. Non-B strains were highly diverse and included 6 subtypes, 10 CRFs, and several URFs, all of which contributed to the great overall diversity of HIV-1 found throughout France. CRF02_AG circulates widely in France, due to its close links with West Africa where this form is prevalent [1] . Recently, we showed that 8.3% of the patients diagnosed at PHI harbored mosaic forms involving often CRFO2_AG [35] . The recent description of 7 URFs involving subtype B and CRF02_AG also highlights the growing complexity of HIV-1 molecular diversity in France [36] .
Our observations are consistent with results from other European countries [37, 38] . Yerly et al [39] noted a steady increase (30%) between 1996 and 2005 in non-B subtypes among 822 recently infected individuals in Switzerland. More recently, a significant increase in the proportion of non-B subtypes was found there, up to 33% in 2009 [40] .
In France, subtype B was initially associated with the French MSM and heterosexual populations, and the CRF02_AG strain was associated with heterosexual migrants from sub-Saharan Africa. Both of these viral subtypes now cocirculate in all risk groups. We found that a substantial but stable proportion of the French heterosexual PHI patients are infected with a non-B subtype (38.7% for men and 41% for women). The proportion of subtype B infections among African patients living in France is also substantial (22.5%) and contrasts with the finding that this subtype is very rare in sub-Saharan Africa [1] . The proportion of homo-bisexual French patients infected with a non-B virus was >2-fold higher after 2004 compared to before 2000. Both the presence of non-B infections in French citizens and subtype B infections in sub-Saharan Africans suggest that these 2 initially distinct epidemics are now connected, especially given that migrants from sub-Saharan Africa who harbor a subtype B strain during PHI are much more likely to have acquired their HIV infection in France.
Although a number of studies were performed in Western countries to analyze the effect of viral subtype on treatment responses, these studies were limited by short follow-ups or small sample sizes or because they analyzed all non-B subtypes as a single group [22, 24, 25, 41] .
This study is novel in its comparison of responses of patient treatment since PHI according to their viral subtype. In patients infected with a CRF02_AG or another non-B virus, virological responses at M6, M12, and M24 following cART initiation were at least comparable to, or even better than, those of patients infected with a B subtype. Our findings were similar after excluding patients of African origin and are in line with those of white patients chronically infected with non-B subtypes who exhibited higher virological success rates during cART than patients infected with B subtypes [23] .
In Cascade, a large collaborative study including 1379 seroconverters patients, the virological and immunological responses to cART were similar across all studied subtypes (A, B, C, CRF02_AG, CRF01_AE, and other CRFs), cART having been initiated at various times following seroconversion (G. Touloumi et al, CROI, 2011, Boston). In an ethnically diverse HIV-1-infected cohort in south London, no difference in the initial virological response to cART was observed between B and all non-B subtypes combined (A, C, D, and CRF02_AG) [42] . Similarly, in a large cohort of 2116 chronically infected patients (66 A, 1550 B, 272 C, 41 D, and 57 CRF02_AG), treated patients infected with a non-B subtype were as likely to achieve viral load suppression as persons infected with a subtype B [43] . These findings of similar virological response prevalence among different subtypes are consistent with those of previous studies that compared the responses to antiretroviral therapy according to HIV-1 subtype [24-26, 44, 45] .
We found that the immunological responses to cART between 1 and 18 months of patients infected with a CRF02_AG strain were better than those of patients infected with a subtype B virus. Similar results were found for other non-B viruses, although of borderline significance. Most previous studies did not find any significant differences among different HIV-1 subtypes in the rates of CD4 + T-cell increases after cART initiation [43, 46] . In 2007, de Arellano et al [47] demonstrated that CD4 + T-cell count gains were not influenced by ethnicity or by HIV-1 subtype, as long as plasma viremia remained undetectable. We still found better CD4 increases in those non-B subtypes after adjusting for gender, excluding African patients, only considering boosted PI-containing regimens or only virologically suppressed patients. Differences between our findings and those of previous studies might be explained by the rather high CD4 + T-cell counts of our population.
CONCLUSIONS
Over the last 15 years, the proportion of non-B subtypes in the HIV-1 epidemic in France has significantly increased up to 28%, and these viruses now exhibit a wide diversity. This is the first study to our knowledge comparing the virological and immunological responses of patients who were infected with different HIV subtypes and who began first-line cART regimens soon after primary infection. Patients infected with a CRF02_AG strain or an another non-B subtype virus had virological responses until M24 that were at least similar to those of patients infected with HIV subtype B and had better immunological responses between 1 and 18 months. Our results are encouraging for countries where CRF02_AG strains predominate in view of the increasing availability of cART in such countries. Intercept, at cART initiation; reference, subtype B.
Notes
Abbreviations: cART, combination antiretroviral therapy; HIV, human immunodeficiency virus; SE, standard error. a Adjusted for gender and plasma HIV-RNA at inclusion (≤5 log copies/mL, >5 log copies/mL).
b Difference between CRF02 and B subtypes.
c Difference between other non-B and B subtypes.
